Fig. 5
From: Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer
SKLB325 has strong therapeutic effects on intraperitoneal dissemination xenograft mouse models. a SKLB325 has strong therapeutic effects on a SKOV3 intraperitoneal dissemination xenograft mouse model: Intraperitoneal tumor weight of each group; number of tumors≥3 mm of each group; mice treated with SKLB325 showed no toxicity-dependent weight loss. b SKLB325 has strong therapeutic effects on an ES2 intraperitoneal dissemination xenograft mouse model: Ascites volume of each group; intraperitoneal tumor weight of each group; mice treated with SKLB325 showed no toxicity-dependent weight loss. c SKLB325 has strong therapeutic effects on a CP70 intraperitoneal dissemination xenograft mouse model: Number of tumours that were ≥3 mm in each group; Number of tumours that were ≤3 mm in each group; Intraperitoneal tumor weight of each group; Mice treated with SKLB325 showed no toxicity-dependent weight loss. d SKLB325 has strong therapeutic effects on an A2780s intraperitoneal dissemination xenograft mouse model: Number of tumors that were ≥3 mm in each group; Number of tumors that were ≤3 mm in each group; Intraperitoneal tumor weight of each group; Mice treated with SKLB325 showed no toxicity-dependent weight loss. Values are the mean ± SD; n = 5–7 mice/group. *p < 0.05, **p < 0.01, ***p < 0.001, SKLB325 group versus control and vehicle groups, respectively. Control: without any treatment; Vehicle: the same dose of DMSO accompanied with NS. e Kaplan–Meier survival curve for tumor-bearing mice treated with control, vehicle, or SKLB325 using the SKOV3 intraperitoneal dissemination xenograft mouse model. Two mice in the SKLB325-treated group survived the entire 120 days after i.p. inoculation, when the planned experimental period ended. Survival was significantly longer in the mice treated with SKLB325 compared with the control and vehicle groups (log-rank test, p = 0.000), and there was no significant difference between the control and vehicle groups (p > 0.05). The median survival of the SKLB325 group was 75 days versus 51 days and 52 days in the control and vehicle groups, respectively; n = 10 for each group. f Measurement of protein levels of P53 and PUMA by western blotting in vivo on the SKOV3 intraperitoneal dissemination xenograft mouse model. g Immunohistochemistry of p53 and PUMA in tumor tissue in the SKOV3 intraperitoneal dissemination xenograft mouse model. Magnification: ×200; scale bar, 50 μm
